Hualan Biochemicals shuts down five blood stations and lost profits in the first half of the year

Hualan Bioengineering Co., Ltd. (Hualan Bio, 002007) expects poor performance for the first half of this year.

According to a quarterly report released by Hualan Bios last night, during the reporting period, the company realized total revenue of 274 million yuan, an increase of 3.46% year-on-year, and a net profit of 131 million yuan, a slight decrease of 2.53% year-on-year. Hualan Biological Projected. From January to June 2012, the company's net profit was 218 million yuan, a decrease of 0% to 20% year-on-year.

Hualan Bio pointed out that the change in performance was due to the publication of the “Guangdong Province Blood Collection and Supply Institution Planning” document issued by the Guizhou Provincial Department of Health in July 2011. Five apheresis plasma stations stopped the plasma collection on August 1, 2011, and raw material plasma. The decrease leads to a decrease in the sales revenue of blood products and a drop in net profit.

Hualan Bio pointed out in its 2011 annual report that there was a strong demand for blood products and sales were good. There was no order production, but the closure of the plasma collection site resulted in a reduction of raw material plasma supply by nearly 50%, while the price of blood products was basically stable. The main raw materials were plasma. The cost rose slightly, while the price of raw and auxiliary materials in other parts increased to varying degrees. Data show that the operating costs of blood products in 2011 increased by 3.88% over the same period of last year, operating income decreased by 0.55%, and gross profit margin decreased by 1.35%.

However, Hualan Biological also anticipates that in the first half of 2012, the Chongqing subsidiary will pass GMP certification, and the plasma collected by the six plasma apheresis stations can be officially produced and sold, which will gradually make up for the adverse effects of Guizhou plasma shut down.

A quarterly report disclosed that during the reporting period, the income of the H1N1 influenza virus split vaccine was confirmed to be 106 million yuan, and the amount of money received was 78.551 million yuan. But this is not new contract revenue this year. Previous announcements showed that during the outbreak of influenza A, Hualan Bio received a total of 52.25 million doses of the H1N1 influenza virus splitting vaccine storage and storage task from the Consumer Products Industry Division of the Ministry of Industry and Information Technology of the People's Republic of China, of which 7.14 million doses were collected and stored by the state. The epidemic has subsided and has remained in the warehouse. No financial payments have been made. After coordination, in February 2012, it received a total of 78.513 million yuan from the national collection and storage of H1N1 influenza virus split vaccine.

In fact, the once-a-day vaccine for lethal vaccines by Hualan Biotech has basically stopped selling. The 2011 annual report shows that in 2011, a total of 17.2213 million yuan of vaccine revenue was generated at a cost of 0 yuan, and the revenue was all paid by the above-mentioned Ministry of Industry and Information Technology.

Hualan Bio closed at 24.34 yuan/share yesterday, up 1.76%.